Bruker Corporation has announced a global settlement with 10x Genomics, effectively ending all ongoing litigation between the two companies. The settlement includes global patent cross license agreements, leading to the dismissal of multiple lawsuits and administrative proceedings in various countries, including the United States and Germany. This resolution allows both companies to focus on their contributions to the scientific community without the distraction of legal disputes.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。